Prolonged Recovery Time from Zoledronic Acid Induced Acute Tubular Necrosis: A Case Report and Review of the Literature

Table 2

Profile of reported cases of ARF associated with Zoledronic acid.

Author	Case	Underlying; disease	Baseline creatinine (mg/dL)	Bisphosphonate use prior to Zometa	Dose of Zometa; (mg)	Recovery time; (months)	Dialysis requirement; (yes/no)	Serum creatinine; peak/end; (mg/dL)
Ramazzina et al. [1]	1	MM	U/K	Pamidronate × 4 doses	4 mg	9	Yes	ESRD
Markowitz et al. [2]	2	MM	1.5	Pamidronate × 13 doses	4 mg	4	No	4.0/2.4
Markowitz et al. [2]	3	Paget’s	1.5	Pamidronate × 10 doses	4 mg	4	No	3.8/2.6
Markowitz et al. [2]	4	MM	1.3	Pamidronate × 45 doses	4 mg	9	No	2.5/2.3
Markowitz et al. [2]	5	MM	1.4	Pamidronate × 22 doses	4 mg	4	No	2.6/1.6
Markowitz et al. [2]	6	MM	1.5	Pamidronate × 2 doses	4 mg	3	No	5.5/3.0
Markowitz et al. [2]	7	Prostate Cancer	1.0	Pamidronate × 9 doses	4 mg	4	No	2.0/1.7
Koike et al. [3]	8	MM	U/K	None	4 mg	7	Yes	7.3/UK
Joensuu [4]	9	Prostate Cancer	0.7	None	4 mg	5	No	1.2/0.7
Our patient	10	Breast Cancer	0.8	None	4 mg	>14	No	8.0/3.0

MM: multiple myeloma.
ARF: acute renal failure.